ArticlemBio2019
Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells.
Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface.Immunity · 2024Article
- Highly Cross-Reactive and Protective Influenza A Virus H3N2 Hemagglutinin- and Neuraminidase-Specific Human Monoclonal Antibodies.Microbiology spectrum · 2023Article
- Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody.Viruses · 2023Article
- Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B.PloS one · 2023Article
- A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases.Nature communications · 2022Article
- Article
- Cross-Protection Induced by Virus-like Particles Derived from the Influenza B Virus.Biomedicines · 2022Article
- Review
- Article
- The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination.Vaccines · 2021Review
- Article
- Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.Viruses · 2021Review
- Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.Journal of virological methods · 2021Article
- Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective.Immunity · 2020Article
- Review
- Neuraminidase antigenic drift of H3N2 clade 3c.2a viruses alters virus replication, enzymatic activity and inhibitory antibody binding.PLoS pathogens · 2020Article
- Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans.Cell reports. Medicine · 2020Article
- Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.Journal of virology · 2019Article
- Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 ProteinsFrontiers in microbiology · 2019Article
- The Quest for a Truly Universal Influenza Vaccine.Frontiers in cellular and infection microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Although most seasonal inactivated influenza vaccines (IIV) contain neuraminidase (NA), the extent and mechanisms of action of protective human NA-specific humoral responses induced by vaccination are poorly resolved. Due to the propensity of influenza virus for antigenic drift and shift and its tendency to elicit predominantly strain-specific antibodies, humanity remains susceptible to waves of new strains of seasonal viruses and is at risk from viruses with pandemic potential for which limited or no immunity may exist. Here we demonstrate that the use of IIV results in increased levels of influenza B virus (IBV) NA-specific serum antibodies. Detailed analysis of the IBV NA B cell response indicates concurrent expansion of IBV NA-specific peripheral blood plasmablasts 7 days after IIV immunization which express monoclonal antibodies with broad and potent antiviral activity against both IBV Victoria and Yamagata lineages and prophylactic and therapeutic activity in mice. These IBV NA-specific B cell clonal lineages persisted in CD138
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.